- Home
- IMNM vs TDC Comparison
IMNM vs TDC Comparison
Compare IMNM & TDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | TDC |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | IMNM | TDC |
|---|---|---|
| Price | $19.35 | $31.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $32.80 | ★ $34.78 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | 16.38 |
| EPS | N/A | ★ 3.47 |
| Revenue | $6,941,000.00 | ★ $2,156,000,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $1,127.34 | $1.44 |
| P/E Ratio | ★ N/A | $9.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.96 | $19.83 |
| 52 Week High | $27.65 | $41.78 |
Technical Indicators
Market Signals| Indicator | IMNM | TDC |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 46.04 |
| Support Level | $19.28 | $29.25 |
| Resistance Level | $23.00 | $32.03 |
| Average True Range (ATR) | 0.84 | 1.40 |
| MACD | 0.21 | -0.42 |
| Stochastic Oscillator | 49.16 | 39.77 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.